Case study shows boost in therapy initiation and adherence when AI-enabled personalized communications are deployed
AllazoHealth, the pioneer in driving therapy initiation, adherence, and health outcomes with artificial intelligence (AI)-powered personalization, today released a case study on a top 10 rare diseases pharma company’s use of AI-enabled personalization for communications to increase therapy initiation and decrease therapy discontinuation. The therapies had a variety of administration methods including clinic infusion, home infusion, self-injection, and oral.
The pharma company wanted to find ways to enhance the patient’s therapy journey, improve patient support programs, and increase initiation and adherence of their medications. The company was supporting patients with live phone calls with nurses, which are high touch and costly.
AllazoHealth’s solution was implemented to personalize different patient support programs for about 10,000 patients with a goal of improving onboarding, medication initiation and adherence, and physician follow up across the company’s medications treating multiple therapeutic areas. Each day, AI technology personalized multi-channel communications (such as live call, SMS text, and email) to patients, caregivers, infusion centers, and prescribers. The AI solution informed decisions for each communication, including:
- Prioritization of communication
- Number of attempts
- Timing of communications (day of week and timing in relation to events), for both initial and follow-up attempts
- Frequency of communication
- Selection of content and topics that should be communicated
- When pending communications should be canceled
Results show more patients started therapy and more stayed on therapy:
- Increased therapy initiation by 10.4%
- Decreased therapy discontinuation by 7.3%
Qualitative results were also positive. The company’s patient service and adherence strategy executives stated the technology was a “great investment” because patients were initiating therapy and staying on them to realize improved health outcomes. One executive said, “Patients seemed to benefit from the overall experience, as well as the nurse specialists who needed to complete fewer outreach calls to patients and had an overall feeling of success in their mission to engage with patients and ‘make a difference in the patients’ lives.'”
AllazoHealth CEO William Grambley said, “The outcomes of the case study exceeded initial goals of reducing non-clinical/actionable therapy discontinuation rates and increasing therapy initiation rates. AllazoHealth was able to predict individual medication behaviors and personalize patient communications with optimal content, and the right timing, to proactively drive the next best action to achieve measurable results for better health outcomes.”
Case Study: AllazoHealth Partners with Top 10 Rare Diseases Pharma Company – AI-Based Targeted, Personalized Communications Boosts Initiation and Adherence
About AllazoHealth
AllazoHealth is the pioneer driving therapy initiation, adherence, and health outcomes with AI-powered personalization. The technology optimizes patient programs by personalizing their experience. It has proven results across therapeutic areas from mass market to specialty and rare disease therapies. Using identified patient data and predictive AI, AllazoHealth creates the optimal engagement for each patient by personalizing every communication. AllazoHealth targets the right patients with the right message at the right time via the right channels - at scale - maximizing the impact and efficiency of pharmaceutical patient marketing and patient support programs. Built within Microsoft Azure, the platform is fully HIPAA compliant and HITRUST certified. AllazoHealth is named in PM360's Innovation Issue and is the winner of the FiercePharma Innovation Award. Learn more at https://allazohealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241031666396/en/
Contacts
Media Contact:
Hilary McCarthy
774.364.1440
hilary@fordhutmanmedia.com
